<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34170084</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1942-7611</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug testing and analysis</Title>
          <ISOAbbreviation>Drug Test Anal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>What's in fake 'Xanax'?: A dosage survey of designer benzodiazepines in counterfeit pharmaceutical tablets.</ArticleTitle>
        <Pagination>
          <StartPage>525</StartPage>
          <EndPage>530</EndPage>
          <MedlinePgn>525-530</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/dta.3119</ELocationID>
        <Abstract>
          <AbstractText>The identification of a range of different drugs within counterfeit benzodiazepine tablets has been widely reported; however, limited information is available on the dosage of these products. A rapid dosage survey of 46 counterfeit benzodiazepine tablets from 20 seizures was conducted over a 6-month period between April and September 2020. Existing methods utilised for the determination of benzodiazepines in toxicology specimens were applied to assess the dosage of four benzodiazepines detected across five different counterfeit benzodiazepine presentations. The highest dosage variation was observed for etizolam with a range of 0.7-8.3 mg per tablet. This report demonstrates the variability in drug content and dosage that can occur between visually similar counterfeit tablets, even when co-packaged within the same seizure, highlighting the potential public harm posed by these counterfeit medications.</AbstractText>
          <CopyrightInformation>© 2021 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blakey</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-3806-3977</Identifier>
            <AffiliationInfo>
              <Affiliation>Forensic Chemistry, Queensland Health Forensic and Scientific Services, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>Amanda</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Forensic Toxicology, Queensland Health Forensic and Scientific Services, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matheson</LastName>
            <ForeName>Abbey</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Forensic Chemistry, Queensland Health Forensic and Scientific Services, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Griffiths</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Forensic Toxicology, Queensland Health Forensic and Scientific Services, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Drug Test Anal</MedlineTA>
        <NlmUniqueID>101483449</NlmUniqueID>
        <ISSNLinking>1942-7603</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058110">Counterfeit Drugs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013607">Tablets</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12794-10-4</RegistryNumber>
          <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="Y">Alprazolam</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058110" MajorTopicYN="Y">Counterfeit Drugs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Etizolam</Keyword>
        <Keyword MajorTopicYN="N">NPS</Keyword>
        <Keyword MajorTopicYN="N">benzodiazepines</Keyword>
        <Keyword MajorTopicYN="N">counterfeit</Keyword>
        <Keyword MajorTopicYN="N">dosage</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>8</Hour>
          <Minute>51</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34170084</ArticleId>
        <ArticleId IdType="doi">10.1002/dta.3119</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology. 2019;73:8-16. https://doi.org/10.1016/j.neuro.2019.02.015</Citation>
        </Reference>
        <Reference>
          <Citation>Moosman B, Auwärter V. Designer benzodiazepines: Another class of new psychoactive substances. In: Maurer HB, Brandt SD, eds. New psychoactive subtances pharmacology, clinical, forensic and analytical toxicology. Switzerland: Springer; 2018:383-410.</Citation>
        </Reference>
        <Reference>
          <Citation>European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs: The misuse of benzodiazepines among high risk opioid users in Europe, 2018. https://www.emcdda.europa.eu/system/files/publications/2733/Misuse%20of%20benzos_POD2015.pdf. Accessed August 5, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test Anal. 2018;10(1):37-53. https://doi.org/10.1002/dta.2211</Citation>
        </Reference>
        <Reference>
          <Citation>European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances: Global markets, global threats and the COVID-19 Pandemic, 2020. https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf. Accessed December 21, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>European Monitoring Centre for Drugs and Drug Addiction. New benzodiazepines in Europe-A review, 2021. https://www.emcdda.europa.eu/system/files/publications/13759/TD0221596ENN_002.pdf Accessed 9 June, 2021</Citation>
        </Reference>
        <Reference>
          <Citation>United Nations Office on Drugs and Crime. Global smart update: Non-medical use of benzodiazepines: a growing threat to public health?. Volume 18 September 2017. https://www.unodc.org/documents/scientific/Global_SMART_Update_2017_Vol_18.pdf. Accessed June 28, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>May C, Downey C, Power JD, Kavanagh PV. An unusual detection of tert-butyl-4-anilinopiperidine-1-carboxylate in seizures of falsified ‘Xanax’ tablets and in items in a suspected heroin seizure submitted by Irish law enforcement. Drug Test Anal. 2020;12(9):1387-1392. https://doi.org/10.1002/dta.2884</Citation>
        </Reference>
        <Reference>
          <Citation>Ntoupa P-SA, Papoutsis II, Dona AA, Spiliopoulou CA, Athanaselis SA. A fluorine turns a medicinal benzodiazepine into NPS: The case of flualprazolam. Forensic Toxicology. 2021;39:368-376. https://doi.org/10.1007/s11419-020-00565-4</Citation>
        </Reference>
        <Reference>
          <Citation>Welsh Emerging Drugs and Identification of Novel Substances Project. Annual Report 2018-2019. https://wedinos.org/resources/downloads/Annual_Report_201819.pdf. Accessed February 27, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Arens AM, van Wijk XM, Vo KT, Lynch KL, Wu AH, Smollin CG. Adverse effects from counterfeit alprazolam tablets. JAMA Intern Med. 2016;176(10):1554-1555. https://doi.org/10.1001/jamainternmed.2016.4306</Citation>
        </Reference>
        <Reference>
          <Citation>Tobias S, Shapiro AM, Grant CJ, Patel P, Lysyshyn M, Ti L. Drug checking identifies counterfeit alprazolam tablets. Drug Alcohol Depend. 2021;218:108300. https://doi.org/10.1016/j.drugalcdep.2020.108300</Citation>
        </Reference>
        <Reference>
          <Citation>Drugsdata.org. 2019. https://www.drugsdata.org/view.php?id=7996. Accessed February 27, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Energy Control-International.org. 2019. https://energycontrol-international.org/alert-fake-alprazolam-pills-and-powders-containing-antihistamine-mixture/. Accessed February 27, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Nielsen S, McAuley A. Etizolam: A rapid review on pharmacology, non-medical use and harms. Drug Alcohol Rev. 2020;39(4):330-336. https://doi.org/10.1111/dar.13052</Citation>
        </Reference>
        <Reference>
          <Citation>Bohnenberger K, Liu MT. Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil. Ment Health Clin. 2019;9(3):133-137. https://doi.org/10.9740/mhc.2019.05.133</Citation>
        </Reference>
        <Reference>
          <Citation>Blumenberg A, Hughes A, Reckers A, Ellison R, Gerona R. Flualprazolam: report of an outbreak of a new psychoactive substance in adolescents. Pediatrics. 2020;146(1):e20192953. https://doi.org/10.1542/peds.2019-2953</Citation>
        </Reference>
        <Reference>
          <Citation>Rohrig TP, Osawa KA, Baird TR, Youso KB. Driving impairment cases involving etizolam and flubromazolam. J Anal Toxicol. 2021;45(1):93-98. https://doi.org/10.1093/jat/bkaa050</Citation>
        </Reference>
        <Reference>
          <Citation>Kriikku P, Rasanen I, Ojanpera I, Thelander G, Kronstrand R, Vikingsson S. Femoral blood concentrations of flualprazolam in 33 postmortem cases. Forensic Sci Int. 2020;307:110101. https://doi.org/10.1016/j.forsciint.2019.110101</Citation>
        </Reference>
        <Reference>
          <Citation>Therapeutic Goods Administration. Counterfeit Alprazolam 2 mg and Kalma 2 tablets Safety Advisory. 2020. https://www.tga.gov.au/alert/counterfeit-alprazolam-2mg-and-kalma-2-tablets. Accessed February 27, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Nash C, Butzbach D, Stockham P, et al. A fatality involving furanylfentanyl and MMMP, with presumptive identification of three MMMP metabolites in urine. J Anal Toxicol. 2019;43(4):291-298. https://doi.org/10.1093/jat/bky099</Citation>
        </Reference>
        <Reference>
          <Citation>Huppertz LM, Moosmann B, Auwärter V. Flubromazolam-basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal. 2018;10(1):206-211. https://doi.org/10.1002/dta.2203</Citation>
        </Reference>
        <Reference>
          <Citation>Drugsdata.org. 2020. https://www.drugsdata.org/view.php?id=9019. Accessed June 18, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Drugs.com. 2021. https://www.drugs.com/imprints/031-r-7269.html Accessed June 18, 2021</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
